SEC Form 4 · accession 0001856094-26-000008
RECURSION PHARMACEUTICALS, INC. · RXRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Blake Borgeson
Director
Period of report
Jun 2, 2026
Accepted (ET)
Jun 4, 2026 · 5:04 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001601830
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Class A Common Stock | Jun 2, 2026 | S | 30,000 | $3.68 | D | 6,169,863 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 31, 2025.